- Home
- ASRT vs XFOR Comparison
ASRT vs XFOR Comparison
Compare ASRT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- XFOR
- Stock Information
- Founded
- ASRT 1995
- XFOR 2014
- Country
- ASRT United States
- XFOR United States
- Employees
- ASRT N/A
- XFOR N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASRT Health Care
- XFOR Health Care
- Exchange
- ASRT Nasdaq
- XFOR Nasdaq
- Market Cap
- ASRT 79.1M
- XFOR 84.3M
- IPO Year
- ASRT 1997
- XFOR N/A
- Fundamental
- Price
- ASRT $0.95
- XFOR $3.04
- Analyst Decision
- ASRT Strong Buy
- XFOR Strong Buy
- Analyst Count
- ASRT 1
- XFOR 3
- Target Price
- ASRT $3.00
- XFOR $34.17
- AVG Volume (30 Days)
- ASRT 222.4K
- XFOR 1.0M
- Earning Date
- ASRT 11-10-2025
- XFOR 11-12-2025
- Dividend Yield
- ASRT N/A
- XFOR N/A
- EPS Growth
- ASRT N/A
- XFOR N/A
- EPS
- ASRT N/A
- XFOR N/A
- Revenue
- ASRT $117,099,000.00
- XFOR $32,774,000.00
- Revenue This Year
- ASRT N/A
- XFOR $1,313.84
- Revenue Next Year
- ASRT $5.84
- XFOR N/A
- P/E Ratio
- ASRT N/A
- XFOR N/A
- Revenue Growth
- ASRT N/A
- XFOR 5721.31
- 52 Week Low
- ASRT $0.51
- XFOR $1.35
- 52 Week High
- ASRT $1.38
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- ASRT 76.35
- XFOR 48.54
- Support Level
- ASRT $0.79
- XFOR $2.88
- Resistance Level
- ASRT $0.83
- XFOR $3.79
- Average True Range (ATR)
- ASRT 0.04
- XFOR 0.38
- MACD
- ASRT 0.01
- XFOR -0.12
- Stochastic Oscillator
- ASRT 88.81
- XFOR 10.76
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.